Clinical Guideline
Injectable HPC is recommended by the SMFM to reduce the risk of preterm birth for clinically indicated patients2
![smfm clinical guideline chart](https://makenahcp.com/wp-content/uploads/2019/06/smfm-clinical-guideline-chart.png)
Per the 2017 SMFM statement on choice of progestogen, vaginal progesterone should not be considered a substitute for HPC in these at‑risk women.3
Adapted from the SMFM Clinical Guideline published in the May 2012 American Journal of Obstetrics & Gynecology.2
Emphasis added to highlight patient identification and initiation, and duration of therapy.
HPC=hydroxyprogesterone caproate; SMFM=Society for Maternal-Fetal Medicine; PTB=preterm birth; SPTB=spontaneous preterm birth; TVU=transvaginal ultrasound; CL=cervical length.
In a clinical study, comparable bioavailability was seen between Makena Auto-Injector dosed subcutaneously (1.1 mL; back of upper arm) and Makena dosed IM (1 mL; gluteus maximus).1*
*In a single-dose, open-label, randomized, parallel design bioavailability study in 120 healthy post-menopausal women.